Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: relationship to inhibition of prostaglandin cyclooxygenase.

M F Hughes, R P Mason and T E Eling
Molecular Pharmacology August 1988, 34 (2) 186-193;
M F Hughes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R P Mason
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T E Eling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Prostaglandin H synthase (PHS) hydroperoxidase-mediated metabolism of phenylbutazone and the relationship of this metabolism to the inhibition of PHS cyclooxygenase by phenylbutazone was investigated. Phenylbutazone was metabolized to several intermediates and metabolites. A phenylbutazone carbon-centered radical (aN = 14.6 G) formed by PHS hydroperoxidase was trapped by 2-methyl-2-nitrosopropane and detected by ESR in incubations with ram seminal vesicle microsomes. 4-Hydroperoxy- and 4-hydroxyphenylbutazone were isolated from incubations of phenylbutazone with either ram seminal vesicle microsomes or horseradish peroxidase. Phenylbutazone (100 microM-2 mM) inhibited PHS cyclooxygenase in incubations of PHS apoenzyme reconstituted with hematin. Phenylbutazone (5-250 microM) did not inhibit PHS cyclooxygenase in incubations of PHS apoenzyme reconstituted with manganese protoporphyrin IX, which lacks hydroperoxidase activity. Thus, metabolism of phenylbutazone by PHS hydroperoxidase is required for it to inhibit PHS cyclooxygenase. 4-Hydroperoxy- and 4-hydroxyphenylbutazone were ineffective inhibitors of PHS cyclooxygenase. Other hydroperoxides that easily rearrange to peroxyl radicals were potent inhibitors of PHS cyclooxygenase, suggesting that the phenylbutazone peroxyl radical may be the inhibitor. 4-Hydroperoxyphenylbutazone was not reduced to 4-hydroxyphenylbutazone by PHS hydroperoxidase. We propose that 4-hydroxyphenylbutazone formation occurs by a nonenzymatic reaction of two phenylbutazone peroxyl radicals and their subsequent rearrangement to alkoxy radicals, which abstract hydrogen atoms. Our data indicate the importance of PHS hydroperoxidase in the inactivation of PHS cyclooxygenase by peroxides.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 34, Issue 2
1 Aug 1988
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: relationship to inhibition of prostaglandin cyclooxygenase.
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: relationship to inhibition of prostaglandin cyclooxygenase.

M F Hughes, R P Mason and T E Eling
Molecular Pharmacology August 1, 1988, 34 (2) 186-193;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: relationship to inhibition of prostaglandin cyclooxygenase.

M F Hughes, R P Mason and T E Eling
Molecular Pharmacology August 1, 1988, 34 (2) 186-193;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics